论文信息 - Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) - 字舞流文

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

H. Linden | C. Hudis | N. Rosen | A. Stopeck | S. Modi | W. Ma | A. Hannah | S. Sugarman | K. Kersey | Robert A. Johnson | Robert Johnson